Literature DB >> 20358435

Statistical characterization of QT prolongation.

Robert Schall1, Arne Ring.   

Abstract

The appropriate assessment of QT prolongation remains controversial. We suggest that before the relative merits of various methods can be evaluated, we must state what we assume an assessment of QT prolongation should be about. As a general framework for the assessment of QT prolongation we propose that an assessment of "absolute" or "uncorrected" QT prolongation is properly carried out through a between-treatment (active versus placebo) comparison of the marginal distributions of QT data; an assessment of "heart rate corrected" QT prolongation is carried out through a between-treatment comparison of the conditional distributions of QT data (conditional on RR interval or heart rate). Under this general framework, conditional QT prolongation is, in general, a function of RR interval, and we discuss three possible summary characteristics for that function. We show how current procedures for the assessment of QT prolongation relate to the general approach (that is, to between-treatment contrasts of the marginal and conditional expectation of the QT interval), and to each other. It transpires that only the so-called "one-step procedure" can provide a complete characterization of conditional QT prolongation. We show that the "two-step procedure" with data-driven correction provides an unbiased estimate of expected conditional QT prolongation, which may, from a clinical point of view, be a more satisfactory characteristic than the conventional characteristic, QT prolongation at the reference RR interval. We strongly suggest that two-step procedures with fixed correction be abandoned in the analysis of thorough QT/QTc studies: Fixed correction is either redundant (when a drug has no effect on average RR interval), or systematically biased (when a drug does affect average RR interval).

Mesh:

Year:  2010        PMID: 20358435     DOI: 10.1080/10543400903581978

Source DB:  PubMed          Journal:  J Biopharm Stat        ISSN: 1054-3406            Impact factor:   1.051


  3 in total

1.  The DPP-4 inhibitor linagliptin does not prolong the QT interval at therapeutic and supratherapeutic doses.

Authors:  Arne Ring; Andreas Port; E Ulrike Graefe-Mody; Ivette Revollo; Mario Iovino; Klaus A Dugi
Journal:  Br J Clin Pharmacol       Date:  2011-07       Impact factor: 4.335

Review 2.  Overview and management of cardiac adverse events associated with tyrosine kinase inhibitors.

Authors:  Daniel J Lenihan; Peter R Kowey
Journal:  Oncologist       Date:  2013-08-05

3.  Dabigatran does not prolong the QT interval with supratherapeutic exposure: a thorough QT study in healthy subjects.

Authors:  Arne Ring; Karin Rathgen; Joachim Stangier; Paul Reilly; Andreas Clemens; Jeffrey Friedman
Journal:  Clin Drug Investig       Date:  2013-05       Impact factor: 2.859

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.